Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor (TNFi) in rheumatoid arthritis patients who discontinued a first TNFi

Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor (TNFi) in rheumatoid arthritis patients who discontinued a first TNFi

Objectives: To compare the effectiveness of a 2nd TNF inhibitor (TNFi), Tocilizumab (TCZ) and Rituximab (RTX), measured by drug retention and by response rates, in RA patients after discontinuing a first-line TNFi and to clarify the reasons and predictors for discontinuation of a second-line biologi...

Full description

Bibliographic Details
Main Authors: Daniela Santos-Faria, José Tavares-Costa, Mónica Eusébio, Joana Leite Silva, Joana Ramos Rodrigues, Joana Sousa-Neves, Ana Catarina Duarte, Carina Lopes, Ana Valido, Joana Dinis, João Freitas, Mariana Santiago, Raquel Ferreira, Sara Ganhão, Luís Miranda, Daniela Peixoto, Filipa Teixeira, Sérgio Alcino, Carmo Afonso, Maria José Santos
Format: Article
Language:English
Published: Sociedade Portuguesa de Reumatologia 2019-04-01
Series:Acta Reumatológica Portuguesa
Subjects:
Drug survival
Tumour necrosis factor inhibitors
rheumatoid arthritis
rituximab
tocilizumab
Online Access:http://www.actareumatologica.com/files/article/1252_tocilizumab_and_rituximab_have_similar_effectiveness_and_are_both_superior_to_a_second_tumour_necrosis_factor_inhibitor_tnfi_in_rheumatoid_arthritis_patients_who_discontinued_a_first_tnfi__file.pdf

Internet

http://www.actareumatologica.com/files/article/1252_tocilizumab_and_rituximab_have_similar_effectiveness_and_are_both_superior_to_a_second_tumour_necrosis_factor_inhibitor_tnfi_in_rheumatoid_arthritis_patients_who_discontinued_a_first_tnfi__file.pdf

Similar Items